020839 - S - 005
Trade Name: Plavix Tablets

Generic Name(s): (clopidogrel bisulfate)

Sponsor: Sanofi-Synthelabo, Inc.

Agent:

Approval Date: March 15, 2000

Indication: Provides for alternative route for manufacture
NDA 20-839/S-005

Sanofi-Synthelabo, Inc.
Attention: John Purpura
90 Park Avenue
New York, NY 10016

Dear Mr. Purpura:

Please refer to your supplemental new drug application (NDA) dated December 3, 1999 received December 6, 1999 submitted under section 505 (b) of the Federal Food, Drug, Cosmetic Act for Plavix (clopidogrel bisulfate) Tablets, 75 mg.

The supplemental application provides for an alternative route for manufacture of clopidogrel bisulfate synthesis.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Sincerely yours,

/\Si/ ~ 3-15-2000

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I
Division of Cardio-Renal Drug Products (HFD-110)
Office of New Drug Chemistry
Center for Drug Evaluation and Research
CC:
Original NDA 20-839/S-005
HFD-110/Division File
HFD-110/Project Manager
HFD-110/FZielinski
HFD-95
DISTRICT OFFICE
HFD-810/Jsimmons
Init. by: Ksrinivasachar
Drafted by: SO/3/14/00

Approval Date: 11/17/97

APPROVAL
REVIEW OF CHEMISTRY, MANUFACTURING AND CONTROLS
Division of Cardio Renal Drug Products (HFD-110)

1. Chemistry Review # 1

2. NDA # 20-839 S-005 (Prior-Approval Supplement)

3. Name & Address of Applicant
   Sanofi-Synthelabo Inc
   90 Park Avenue
   New York, New York 10016
   (212) 551-4261

   Representative
   John Purpura
   Associate Director CMC
   Drug Regulatory Affairs
   (212) 551-4261

4. Supplement S-005

5. Proprietary Name: Plavix Tablets

6. Nonproprietary Name: Clopidogrel bisulfate

7. Code Name: SR 25990C

8. Chemical Type / Submission Priority: N/A

9. Supplement provides for an alternative route in the clopidogrel bisulfate synthesis.

10. Previous Documents: None

11. Submissions Reviewed:
    (a) Volume 2.1 of Type II DMF (Amendment dated December 3, 1999; pages 118, 123-124, 127, 129, 173-175 and 183-195). Please see attached
    (b) NDA 20839 SCS-005 dated December 3, 1999 [Cover letter, Letter of Authorization,]

12. Pharmacological Category: Prevention of vascular ischemia

13. Rx / OTC: Rx

14. Dosage Form: Tablet (film coated) TCM

15. Strength / Potency: Equivalent to 75 mg base

16. Route of Administration: oral

17. Spots: NO

18. Chemical Name: Methyl(+)-(S)-α-(2-chlorophenyl)-6.7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetate sulfate (1:1)

   CAS #: 120202-66-6  \text{C}_{15}\text{H}_{16}\text{ClNO}_{3}\text{S}\cdot\text{H}_{2}\text{SO}_{4}  \text{MW: base } 321.83  \text{MW: salt } 419.9

19. Related / Supporting Documents: Vol. 2.1 of Type II DMF (Amendment dated December 3, 1999)
Status of Consults and Other Reviews: No consults were requested.

Comments:
(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(Reference: Cover Letter dated December 3, 1999)

Conclusions and Recommendation: I recommend approval of the supplement.

Reviewer: Florian W Zielinski

Date Completed: March 13, 2000